From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
May 14, 2024
Philadelphia, PA, May 14, 2024 – IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that regulatory and government pricing expert Jeff Baab, Vice President of Advisory Services, will speak at Informa’s Pricing and Contracting USA conference. The session will focus on forecasting impacts of best price stacking. The hybrid conference runs May 21-23 in New Orleans, Louisiana.
Wednesday, May 22, 2024Forecasting and Contextualizing Stacking Impacts10:35 am ETAs best price stacking has been causing great noise in the industry, this session will contextualize this movement and how to optimize a unified response. It will cover:
About Jeff BaabJeff Baab is Senior Vice President of IntegriChain’s Advisory Services organization. Previously, Jeff was Vice President of Life Sciences at daVIZta, which merged with IntegriChain in March 2019, where he drove thought leadership activities for the firm. He is a senior member of IntegriChain’s client delivery organization and is a popular speaker at conferences on regulatory updates and trends in government pricing, state pricing transparency, and gross-to-net topics. Jeff has more than 16 years of experience in the Managed Markets industry, and he draws on his extensive compliance and commercial contracting background to best serve the needs of manufacturers — large and small as well as retail, specialty, buy-and-bill, and precision medicine. Jeff earned a Bachelor’s of Science in Finance & Economics from Penn State University.
About IntegriChain’s Advisory ServicesIntegriChain is a drug commercialization partner to a wide range of pharmaceutical manufacturers. From helping emerging companies plan and execute their first-time launch to supporting more than 65% of the top-50 largest manufacturers, IntegriChain’s solutions and services enable manufacturers to get their therapies to the right patients at the right time. IntegriChain’s Operational Consulting team offers broad operational and decision support practice areas that ensure commercialization and access strategies are put into action and deliver the expected results:
Roadmap to Launch: a proven blueprint for success in launching a new pharmaceutical product covering commercial analytics and support, compliance programs, and business and process guidance
Contracts & Pricing Consulting: from compliance and business planning to forecasting and analytics
Gross-to-Net (GTN) Consulting: includes GTN process assessment, GTN profitability assessment, and GTN modeling
ICyte Benchmarks: performance metrics based on the industry’s largest data set for thousands of therapy brands in the ICyte Platform including point-of-care segmentation and contract benchmarking
About IntegriChainIntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Pharma, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.
ContactJennifer Guinan, Sage Strategic Marketing, jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
